Moonwalk Team

Pedro Mendez comes from Synthego, where he led the Analytical R&D team, developing and implementing innovative analytical tools and capabilities in gene editing and cell therapy programs. Also, participated in developing the pre-clinical program of non-viral multiplexed T-cell gene editing.

Before Synthego, Pedro joined Mission Bio, where he developed single-cell multi-omics technologies, including the scDNA, scDNA +CNV, and scDNA + protein modalities. He also led collaborations with pharma partners, KOLs, and beta-testing programs.

Pedro spent four years at the UCSF Thoracic Oncology Program, under the leadership of Dr. David Jablons and Dr. Il-Jin Kim, where he developed NGS and Molecular diagnostics tools for characterizing genomic landscapes of Lung malignancies. Some of the technology developed was licensed to CureSeq Inc, which commercialized it for fast identification of Lung cancer patients eligible for treatment in first line with tyrosine kinase inhibitors.

During the prior 15 years, Pedro focussed on identifying predictive and prognostic biomarkers of cancer patients under the leadership of Dr. Rafael Rosell and Dr. Miquel Taron. During that time, Pedro also became an active member of the Spanish Lung Cancer Grup, where he developed technology for the Molecular characterization of tumor samples in clinical trials.